

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 21, 2020

**INTERNATIONAL ISOTOPES INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**Texas**

(State or Other Jurisdiction of  
Incorporation)

**0-22923**

(Commission File Number)

**74-2763837**

(IRS Employer Identification No.)

**4137 Commerce Circle  
Idaho Falls, Idaho**

(Address of Principal Executive Offices)

**83401**

(Zip Code)

**208-524-5300**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 1.02. Termination of a Material Definitive Agreement.**

As disclosed in April 2019, International Isotopes Inc. (the “Company”) previously entered into a Manufacturing and Supply Agreement (the “Manufacturing Agreement”) with Progenics Pharmaceuticals, Inc. (“Progenics”), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the Company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTERNATIONAL ISOTOPES INC.**

Date: December 28, 2020

By: /s/ Steve T. Laflin  
Steve Laflin  
President and Chief Executive Officer